Digital Diabetes Management Market Growth and Demand Forecast to 2030

The global digital diabetes management market is projected to generate revenue of USD 17.8 billion in 2023. This market is expected to grow at a CAGR of 13.7% from 2024 to 2030, reaching USD 43.4 billion by 2030. According to the International Diabetes Federation, approximately 538 million adults were living with diabetes in 2021. This number is expected to increase to 643 million by 2030 and 783 million by 2045.

Over the past two years, numerous scientific advancements have been made in diabetes care, particularly in smart sensor-based glucose monitoring technology, closed-loop systems, implantable digital medical devices for diabetes management, and wearable and smartphone-based health trackers.

Technological advancements have significantly improved diabetes management, allowing patients and their families to spend less time monitoring blood glucose levels while maintaining a flexible daily schedule. This digital health therapeutics sector is enriched with products such as pre-filled syringes, insulin pumps, and glucose meters with test strips, which compete effectively with traditional methods.

Fundamentally, global progress in diabetes management is driven by advancements in treatments and diagnostic techniques for hyperglycemia. Notably, smart insulin pens, equipped with the I-Sens adapter, measure insulin levels and guide correct injection angles.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/digital-diabetes-management-market-report/report-sample

Key Insights

• In 2023, continuous glucose monitoring (CGM) systems generated the largest revenue share of 40%, due to enhanced features like connectivity with smart devices and customizable notifications based on glucose thresholds.
• The smart insulin pens category is anticipated to grow at a CAGR of 14.3% over the forecast period, driven by AI integration and increased product launches by major companies.
• In March 2022, Novo Nordisk introduced intelligent insulin pens (NovoPen Echo Plus and NovoPen 6) in the U.K., improving treatment efficiency for insulin-dependent diabetes patients through a partnership with the NHS.
• The adoption of smartphones and wearables, an aging population, and the growing need for better IT infrastructure will support the tracking of diabetes applications and blood glucose management, fostering gradual growth in this field.
• Companies are improving patient compliance by incorporating modern apps with advanced features.
• Wearable devices are projected to capture a substantial 70% share of the global digital diabetes management market by the end of the decade.
• CGM systems have received regulatory approvals, and ongoing technical improvements in smart insulin patches contribute to the dominance of wearable devices.
• CGM systems offer comprehensive data, including blood glucose analyses and alerts for abnormal levels, enhancing patient convenience and driving global adoption.
• In 2023, North America accounted for approximately 55% of the diabetes management market's revenue.
• Factors contributing to North America's market dominance include rising diabetes prevalence, technological advancements in digital solutions, high smartphone usage, and the adoption of cloud-based healthcare solutions.
• The region's focus on improving treatment quality, advanced healthcare infrastructure, and the adoption of connected diabetes management applications and remote coaching facilities further propel market growth.